Literature DB >> 23318961

A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR.

M F Kaiser, B A Walker, S L Hockley, D B Begum, C P Wardell, D Gonzalez, F M Ross, F E Davies, G J Morgan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23318961     DOI： 10.1038/leu.2013.12

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  22 in total

Review 1.  Risk Stratification in Multiple Myeloma in Indian Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-14       Impact factor: 0.900

2.  Neutral tumor evolution in myeloma is associated with poor prognosis.

Authors:  David C Johnson; Oleg Lenive; Jonathan Mitchell; Graham Jackson; Roger Owen; Mark Drayson; Gordon Cook; John R Jones; Charlotte Pawlyn; Faith E Davies; Brian A Walker; Christopher Wardell; Walter M Gregory; David Cairns; Gareth J Morgan; Richard S Houlston; Martin F Kaiser
Journal:  Blood       Date:  2017-08-21       Impact factor: 22.113

3.  Subclonal TP53 copy number is associated with prognosis in multiple myeloma.

Authors:  Vallari Shah; David C Johnson; Amy L Sherborne; Sidra Ellis; Frances M Aldridge; Julie Howard-Reeves; Farzana Begum; Amy Price; Jack Kendall; Laura Chiecchio; Suvi Savola; Matthew W Jenner; Mark T Drayson; Roger G Owen; Walter M Gregory; Gareth J Morgan; Faith E Davies; Richard S Houlston; Gordon Cook; David A Cairns; Graham Jackson; Martin F Kaiser
Journal:  Blood       Date:  2018-10-29       Impact factor: 22.113

Review 4.  Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.

Authors:  Ola Landgren; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2013-11-22       Impact factor: 12.531

5.  Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.

Authors:  James Croft; Sidra Ellis; Amy L Sherborne; Kim Sharp; Amy Price; Matthew W Jenner; Mark T Drayson; Roger G Owen; Sally Chown; Jindriska Lindsay; Kamaraj Karunanithi; Hannah Hunter; Walter M Gregory; Faith E Davies; Gareth J Morgan; Gordon Cook; Lilit Atanesyan; Suvi Savola; David A Cairns; Graham Jackson; Richard S Houlston; Martin F Kaiser
Journal:  Leukemia       Date:  2020-12-01       Impact factor: 11.528

6.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

7.  Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Authors:  Charlotte Pawlyn; Lorenzo Melchor; Alex Murison; Christopher P Wardell; Annamaria Brioli; Eileen M Boyle; Martin F Kaiser; Brian A Walker; Dil B Begum; Nasrin B Dahir; Paula Proszek; Walter M Gregory; Mark T Drayson; Graham H Jackson; Fiona M Ross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2014-11-26       Impact factor: 25.476

8.  RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Authors:  Michael A Chapman; Jonathan Sive; John Ambrose; Claire Roddie; Nicholas Counsell; Anna Lach; Mahnaz Abbasian; Rakesh Popat; Jamie D Cavenagh; Heather Oakervee; Matthew J Streetly; Stephen Schey; Mickey Koh; Fenella Willis; Andres E Virchis; Josephine Crowe; Michael F Quinn; Gordon Cook; Charles R Crawley; Guy Pratt; Mark Cook; Nivette Braganza; Toyin Adedayo; Paul Smith; Laura Clifton-Hadley; Roger G Owen; Pieter Sonneveld; Jonathan J Keats; Javier Herrero; Kwee Yong
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

9.  A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.

Authors:  Eileen M Boyle; Paula Z Proszek; Martin F Kaiser; Dil Begum; Nasrin Dahir; Suvi Savola; Christopher P Wardell; Xavier Leleu; Fiona M Ross; Laura Chiecchio; Gordon Cook; Mark T Drayson; Richard G Owen; John M Ashcroft; Graham H Jackson; James Anthony Child; Faith E Davies; Brian A Walker; Gareth J Morgan
Journal:  Genes Chromosomes Cancer       Date:  2014-10-07       Impact factor: 5.006

10.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Authors:  Brian A Walker; Eileen M Boyle; Christopher P Wardell; Alex Murison; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; David C Johnson; Martin F Kaiser; Lorenzo Melchor; Lauren I Aronson; Matthew Scales; Charlotte Pawlyn; Fabio Mirabella; John R Jones; Annamaria Brioli; Aneta Mikulasova; David A Cairns; Walter M Gregory; Ana Quartilho; Mark T Drayson; Nigel Russell; Gordon Cook; Graham H Jackson; Xavier Leleu; Faith E Davies; Gareth J Morgan
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.